Semaglutide

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. The decision to take any medication long-term should be made in consultation with a healthcare provider who knows your full medical history. The GLP-1 medication boom has created an interesting situation: millions of people are now taking drugs that were tested in trials lasting 1-2 years, but many expect to stay on them for decades. The longest trial data we have is about 5 years. That’s substantial, enough to identify most serious adverse effects, but it’s not “lifetime.” ...

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Gallbladder disease and pancreatitis are serious medical conditions. If you experience severe abdominal pain, especially with fever, nausea, or jaundice, seek emergency medical attention immediately. There’s a tradeoff baked into every weight loss method that actually works: rapid weight loss increases your risk of gallstones. This was true long before Ozempic existed, it’s a known complication of very low-calorie diets, bariatric surgery, and any intervention that produces significant weight loss quickly. ...

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. GLP-1 medications like Ozempic should only be used under the supervision of a licensed healthcare provider. Always consult your doctor before making changes to your medication or treatment plan. Nausea is the side effect everyone warns you about with Ozempic. And they’re not wrong, it really is the most common complaint. In the STEP 1 trial, over 44% of people on semaglutide reported nausea at some point PMID: 33567185. That’s almost half. ...

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Fatigue can have many causes, some of which require medical evaluation. Always consult your healthcare provider about persistent fatigue or other concerning symptoms while taking any medication. Fatigue doesn’t get the same attention as nausea when people talk about Ozempic side effects, but it’s surprisingly common. In the STEP 1 trial, about 11% of people on semaglutide reported fatigue, compared to 5% on placebo PMID: 33567185. Online forums are full of people asking some version of “why am I so tired on this medication?” ...

Introduction: The Warning That Worries Millions Open any GLP-1 medication guide — whether for Ozempic, Wegovy, Mounjaro, or Zepbound — and you will encounter the same ominous language: a black box warning about thyroid C-cell tumors. It is the FDA’s strongest safety warning, reserved for drugs with serious or life-threatening risks. For the millions of people now taking these medications for diabetes and weight loss, this warning raises an unsettling question: Am I trading obesity for cancer? ...

Introduction If you are considering medical treatment for obesity in 2026, two names dominate the conversation: Mounjaro (tirzepatide) and Wegovy (semaglutide). Both are once-weekly injectable medications that have transformed the landscape of weight management, producing results that were previously achievable only with bariatric surgery. But they are not interchangeable — they differ in their mechanism of action, the magnitude of weight loss they produce, their side effect profiles, their cardiovascular evidence base, and their cost. ...

Introduction: When the Scale Goes Down and the Hair Follows You started Ozempic — or Wegovy, Mounjaro, or Zepbound — and the weight is finally coming off. The numbers on the scale are dropping, your clothes fit better, and your metabolic health markers are improving. Then you notice it: more hair in your brush. A worrying amount in the shower drain. Thinning at your temples or a widening part line. ...

Introduction: When Menopause Meets the Scale If you’re a woman navigating perimenopause or menopause, you’ve likely noticed something frustrating: the weight management strategies that worked in your 30s and early 40s suddenly seem to have stopped working. You’re not imagining it — menopause brings about genuine physiological changes that make weight loss harder, and weight gain easier, even if your diet and exercise habits haven’t changed at all. The numbers tell a striking story. Research consistently shows that women gain an average of 0.5 to 0.7 kg (1 to 1.5 pounds) per year during the menopause transition, with fat mass increasing disproportionately even when total body weight stays relatively stable PMID: 39761057. This isn’t just about aesthetics — the weight gained during menopause tends to settle as visceral fat around the abdomen, the metabolically dangerous kind linked to cardiovascular disease, type 2 diabetes, and metabolic syndrome. ...

Introduction: PCOS Meets GLP-1 Polycystic ovary syndrome (PCOS) affects an estimated 8–13% of reproductive-age women worldwide, making it the most common endocrine disorder in this population. At its core, PCOS is not just a reproductive condition — it is fundamentally a metabolic disorder. Insulin resistance sits at the center of the pathophysiology for the majority of women with PCOS, driving both the metabolic complications (weight gain, dyslipidemia, progression to type 2 diabetes) and the reproductive manifestations (hyperandrogenism, anovulation, infertility). ...

For years, doctors prescribed GLP-1 medications primarily for blood sugar control and, more recently, for weight loss. But something unexpected kept showing up in the data: people taking these drugs had fewer kidney problems. The FLOW trial, published in the New England Journal of Medicine in 2024, confirmed what many researchers suspected — semaglutide doesn’t just spare the kidneys, it actively protects them. This makes it one of the most promising diabetes kidney medications available today. ...